CoChat
Sign Up
Cited by 40T-cell and Retrovirus StudiesNF-κB Signaling PathwaysViral-associated cancers and disorders

The DOI matches its Crossref record.

Proapoptotic regimes for HTLV-I-transformed cells: targeting Tax and the NF-κB pathway

Kfoury, Y, Nasr, R, Hermine, O, de Thé, H, Bazarbachi, A·2005·Cell Death & Differentiation
DOI 10.1038/sj.cdd.4401624
Open this paper in CoChat — free account

Overview

Integrity signals

Registry

Crossref · 10.1038/sj.cdd.4401624

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • NF-κB pathway is chronically activated in HTLV-1-transformed cell lines, even in the absence of tax expression.

    “Another potential therapeutic target in the treatment of HTLV-1 is NF-κB, as its pathway is chronically activated in HTLV-1-transformed cell lines, even in the absence of tax expression [225].”

    From Current State of Therapeutics for HTLV-1 (2024) · cites this paper as [225]

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 57

  1. Gessain A et al. (1985) Lancet 2: 407–410 · DOI
  2. Gessain A and de The G (1996) Adv. Virus Res. 47: 377–426 · DOI
  3. Mortreux F et al. (2003) Leukemia 17: 26–38 · DOI
  4. Burton M et al. (2000) J. Virol. 74: 2351–2364 · DOI
  5. Yoshida M (2001) Annu. Rev. Immunol. 19: 475–496 · DOI
  6. Waldmann TA et al. (1993) Blood 82: 1701–1712 · DOI
  7. Suzuki T et al. (1999) Virology 259: 384–391 · DOI
  8. Jeang KT et al. (1990) Science 247: 1082–1084 · DOI
  9. Gabet AS et al. (2003) Oncogene 22: 3734–3741 · DOI
  10. Mori N et al. (2001) Virus Genes 22: 279–287 · DOI
  11. Brauweiler A et al. (1997) Virology 231: 135–140 · DOI
  12. Kawakami A et al. (1999) Blood 94: 3847–3854 · DOI
  13. Mahieux R et al. (2000) AIDS Res. Hum. Retroviruses 16: 1677–1681 · DOI
  14. Pise-Masison CA et al. (2000) AIDS Res. Hum. Retroviruses 16: 1669–1675 · DOI
  15. Mesnard JM and Devaux C (1999) Virology 257: 277–284 · DOI
  16. Arnulf B et al. (2002) Blood 100: 4129–4138 · DOI
  17. El-Sabban ME et al. (2002) Blood 99: 3383–3389 · DOI
  18. Grassmann R et al. (1989) Proc. Natl. Acad. Sci. USA 86: 3351–3355 · DOI
  19. Tanaka A et al. (1990) Proc. Natl. Acad. Sci. USA 87: 1071–1075 · DOI
  20. Nerenberg M et al. (1987) Science 237: 1324–1329 · DOI · Paper page
  21. Baeuerle PA and Henkel T (1994) Annu. Rev. Immunol. 12: 141–179 · DOI · Paper page
  22. Zabel U and Baeuerle PA (1990) Cell 61: 255–265 · DOI
  23. Inoue J et al. (1992) Cell 68: 1109–1120 · DOI
  24. Henkel T et al. (1992) Cell 68: 1121–1133 · DOI
  25. Pahl HL (1999) Oncogene 18: 6853–6866 · DOI · Paper page
  26. Chen ZJ et al. (1996) Cell 84: 853–862 · DOI
  27. Yamaoka S et al. (1998) Cell 93: 1231–1240 · DOI
  28. Rothwarf DM et al. (1998) Nature 395: 297–300 · DOI
  29. Tojima Y et al. (2000) Nature 404: 778–782 · DOI
  30. Nakano H et al. (1998) Proc. Natl. Acad. Sci. USA 95: 3537–3542 · DOI
  31. Palombella VJ et al. (1994) Cell 78: 773–785 · DOI
  32. Good L and Sun SC (1996) J. Virol. 70: 2730–2735 · DOI
  33. Sun SC and Ballard DW (1999) Oncogene 18: 6948–6958 · DOI
  34. Xiao G and Sun SC (2000) Oncogene 19: 5198–5203 · DOI
  35. Yin MJ et al. (1998) Cell 93: 875–884 · DOI
  36. Rousset R et al. (1996) Nature 381: 328–331 · DOI
  37. Hirai H et al. (1994) Proc. Natl. Acad. Sci. USA 91: 3584–3588 · DOI
  38. Pepin N et al. (1994) Virology 204: 706–716 · DOI
  39. Bex F et al. (1997) J. Virol. 71: 3484–3497 · DOI
  40. Robek MD and Ratner L (1999) J. Virol. 73: 4856–4865 · DOI
  41. Portis T et al. (2001) Blood 98: 1200–1208 · DOI
  42. Ballard DW et al. (1988) Science 241: 1652–1655 · DOI
  43. Chen GQ et al. (1996) Blood 88: 1052–1061 · DOI
  44. Zhu J et al. (2001) Oncogene 20: 7257–7265 · DOI
  45. Bazarbachi A et al. (1999) Blood 93: 278–283 · DOI
  46. Nasr R et al. (2003) Blood 101: 4576–4582 · DOI
  47. Hemelaar J et al. (2001) J. Virol. 75: 11106–11115 · DOI
  48. Mori N et al. (2002) Blood 100: 1828–1834 · DOI
  49. Dewan MZ et al. (2003) J. Virol. 77: 5286–5294 · DOI
  50. Jentsch S and Schlenker S (1995) Cell 82: 881–884 · DOI
  51. Hershko A and Ciechanover A (1998) Annu. Rev. Biochem. 67: 425–479 · DOI · Paper page
  52. Chiari E et al. (2004) J. Virol. 78: 11823–11832 · DOI
  53. Mitra-Kaushik S et al. (2004) Blood 104: 802–809 · DOI
  54. Satou Y et al. (2004) Leukemia 18: 1357–1363 · DOI
  55. Nasr R et al. (2005) Oncogene 24: 419–430 · DOI
  56. Lau A et al. (1998) Blood 91: 2467–2474 · DOI
  57. Tamiya S et al. (1998) Blood 91: 3935–3942 · DOI

Cited by

Sorted by citations

Metadata

Authors
Kfoury, Y., Nasr, R., Hermine, O., de Thé, H., & Bazarbachi, A.
Affiliations
  • American University of Beirut (LB)
  • Hôpital Necker-Enfants Malades (FR)
  • Centre National de la Recherche Scientifique (FR)
Corresponding author
  • de Thé, H
  • Bazarbachi, A
ORCID
Venue
Cell Death & Differentiation
Publisher
Springer Science and Business Media LLC
Published
2005-04-22
Volume
12
Issue
S1
Pages
871-877
ISSN
  • 1350-9047 (ISSN-L)
  • 1476-5403
DOI
10.1038/sj.cdd.4401624
OpenAlex
W1983486536
Cited by
40
References
0
Citations by year
2025: 1 · 2024: 3 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 1 · 2018: 2 · 2017: 2 · 2014: 3 · 2013: 1 · 2012: 2
FWCI
0.32
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Cell Death and Differentiation (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • American University of Beirut
  • Lady Tata Memorial Trust
  • Tata Trusts
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
  • Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
Keywords
HTLV-1, adult T-cell leukemia/lymphoma, Tax protein, NF-κB signaling, apoptosis, viral oncogenesis, arsenic trioxide, interferon-alpha, proteasome inhibitors, targeted therapy, chemoresistance
MeSH terms
Arsenic Trioxide, Animals, Antineoplastic Agents, Arsenicals, Gene Expression Regulation, Humans, Nitriles, Oxides, Sulfones, T-Lymphocytes, Human T-lymphotropic virus 1, Leukemia-Lymphoma, Adult T-Cell, NF-kappa B, Gene Products, tax, Drug Delivery Systems, Apoptosis, Proteasome Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review